Institut Pasteur

Institut Pasteur and Centre National De La Recherche Scientifique

Armanda Casrouge

Philippe Kourilsky

Matthew Albert

Jean-Pierre Abastado

Yu-Chun Lone

Estelle Mottez

Stanislas Pol

Arnaud Fontanet

Jeremie Decalf

Mostafa Mohamed

David Ojcius

The present invention relates to methods for the treatment of infection, a disease, or a condition using CD26 (DPIV) inhibitors. The present invention also relates to an antibody that binds to the IP-10 protein and a method of monitoring the necessity for administering a CD26 inhibitor to a patient, comprising evaluating a level of sIP-10, a activity of CD26, and/or a level of CXCR3 cells in a sample.

Methods of using sIP-10, CD26 inhibitors and CXCR3 levels in a sample to assess clearance of infection, response to interferon therapy, and treating chronic infections

An altered MHC class I determinant comprises .alpha..sub.1, .alpha..sub.2, .alpha..sub.3, .beta..sub.2 -microglobulin (.beta..sub.2 m) polypeptide domains encoded by a mammalian MHC class I locus in which the .alpha..sub.3 domain is covalently linked to the .beta..sub.2 M domain. An altered MHC class II determinant comprises .alpha..sub.1, .alpha..sub.2, .beta..sub.1, and .beta..sub.2 polypeptide domains encoded by a mammalian MHC class II locus, in which the domains are covalently linked to form a polypeptide comprising the .beta..sub.2 -.alpha..sub.2 -.alpha..sub.1 -.beta..sub.1 domains in sequence. The altered MHC class I and class II determinants can be associated with an antigen to elicit an immune response. The invention can be used in the immunization or treatment of diseases such as AIDS, multiple sclerosis, lupus erythematosus, toxic shock or snake bite.

Altered major histocompatibility complex (MHC) determinant and methods

Growing community of inventors

Draveil, France

Armanda Casrouge